This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hamilton, H. Articles by Falck-Pedersen, E. Search for Related Content PubMed PubMed Citation Articles by Hamilton, H. Articles by Falck-Pedersen, E.

 Previous Article  |  Next Article 

Journal of Virology, August 2004, p. 7874-7882, Vol. 78, No. 15
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.15.7874-7882.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Adeno-Associated Virus Site-Specific Integration and AAVS1 Disruption

Henry Hamilton,¹ Janette Gomos,² Kenneth I. Berns,³ and Erik Falck-Pedersen^1,2*

Molecular Biology Graduate Program, Weill Graduate School of Medical Sciences,¹ Department of Microbiology and Immunology, Hearst Research Foundation, Weill Medical College of Cornell University, New York, New York 10021,² University of Florida College of Medicine, Gainesville, Florida³

Received 23 February 2004/ Accepted 6 April 2004

Adeno-associated virus (AAV) is a single-stranded DNA virus with a unique biphasic lifestyle consisting of both a productive and a latent phase. Typically, the productive phase requires coinfection with a helper virus, for instance adenovirus, while the latent phase dominates in healthy cells. In the latent state, AAV is found integrated site specifically into the host genome at chromosome 19q13.4 qtr (AAVS1), the only animal virus known to integrate in a defined location. In this study we investigated the latent phase of serotype 2 AAV, focusing on three areas: AAV infection, rescue, and integration efficiency as a function of viral multiplicity of infection (MOI); efficiency of site-specific integration; and disruption of the AAVS1 locus. As expected, increasing the AAV MOI resulted in an increase in the percentage of cells infected, with 80% of cells infected at an MOI of 10. Additional MOI only marginally effected a further increase in percentage of infected cells. In contrast to infection, we found very low levels of integration at MOIs of less than 10. At an MOI of 10, at which 80% of cells are infected, less than 5% of clonal cell lines contained integrated AAV DNA. At an MOI of 100 or greater, however, 35 to 40% of clonal cell lines contained integrated AAV DNA. Integration and the ability to rescue viral genomes were highly correlated. Analysis of integrated AAV indicated that essentially all integrants were AAVS1 site specific. Although maximal integration efficiency approached 40% of clonal cell lines (essentially 50% of infected cells), over 80% of cell lines contained a genomic disruption at the AAVS1 integration locus on chromosome 19 (100% of infected cells). Rep expression by itself and in the presence of a plasmid integration substrate was able to mediate this disruption of the AAVS1 site. We further characterized the disruption event and demonstrated that it resulted in amplification of the AAVS1 locus. The data are consistent with a revised model of AAV integration that includes preliminary expansion of a defined region in AAVS1.

---

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Weill Medical College of Cornell University, Box 62, 1300 York Ave., New York, NY 10021. Phone: (212) 746-6514. Fax: (212) 746-8587. E-mail: efalckp{at}med.cornell.edu.

---

Journal of Virology, August 2004, p. 7874-7882, Vol. 78, No. 15
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.15.7874-7882.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Henckaerts, E., Dutheil, N., Zeltner, N., Kattman, S., Kohlbrenner, E., Ward, P., Clement, N., Rebollo, P., Kennedy, M., Keller, G. M., Linden, R. M. (2009). Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proc. Natl. Acad. Sci. USA 106: 7571-7576 [Abstract] [Full Text]  
• Drew, H. R., Lockett, L. J., Both, G. W. (2007). Increased complexity of wild-type adeno-associated virus-chromosomal junctions as determined by analysis of unselected cellular genomes. J. Gen. Virol. 88: 1722-1732 [Abstract] [Full Text]  
• Murphy, M., Gomos-Klein, J., Stankic, M., Falck-Pedersen, E. (2007). Adeno-Associated Virus Type 2 p5 Promoter: a Rep-Regulated DNA Switch Element Functioning in Transcription, Replication, and Site-Specific Integration. J. Virol. 81: 3721-3730 [Abstract] [Full Text]  
• Yamamoto, N., Suzuki, M., Kawano, M.-a., Inoue, T., Takahashi, R.-u, Tsukamoto, H., Enomoto, T., Yamaguchi, Y., Wada, T., Handa, H. (2007). Adeno-Associated Virus Site-Specific Integration Is Regulated by TRP-185. J. Virol. 81: 1990-2001 [Abstract] [Full Text]  
• Wang, H., Lieber, A. (2006). A Helper-Dependent Capsid-Modified Adenovirus Vector Expressing Adeno-Associated Virus Rep78 Mediates Site-Specific Integration of a 27-Kilobase Transgene Cassette. J. Virol. 80: 11699-11709 [Abstract] [Full Text]  
• Adriaansen, J., Vervoordeldonk, M. J. B. M., Tak, P. P. (2006). Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45: 656-668 [Abstract] [Full Text]  
• Adriaansen, J, Tas, S W, Klarenbeek, P L, Bakker, A C, Apparailly, F, Firestein, G S, Jorgensen, C, Vervoordeldonk, M J B M, Tak, P P (2005). Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann Rheum Dis 64: 1677-1684 [Abstract] [Full Text]